Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts
- PMID: 3335786
Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts
Abstract
H-2-deficient variants, selected from the murine lymphoma RBL-5, were recently shown to be less tumorigenic in syngeneic mice compared with the corresponding H-2-positive wild-type cell line. The present study focused on the detailed cellular interactions leading to the specific rejection of H-2-deficient cells in vivo. In vivo experiments with mixed tumor inocula, measuring either tumor outgrowth or rapid elimination, showed that the presence of H-2-positive lymphoma cells did not suppress the rejection of H-2-deficient cells. Conversely, H-2-deficient cells did not activate a rejection of H-2-positive cells. H-2-deficient cells were selectively eliminated even when they were present in a 10-fold excess compared with the H-2-positive lymphoma cells in the same inoculum. In vitro, H-2-deficient cells were more sensitive to killing by spleen cells from mice treated with interferon or natural killer-inducing agents. The presence of cold H-2-deficient cells did not activate the killing of H-2-positive cells, and H-2-positive cells did not inhibit killing of H-2-deficient cells. Such mixing experiments revealed a more efficient cold target inhibition by the H-2-deficient cells, although no difference was seen between these and the H-2-positive wild-type cells in target binding assays. When Thy-1.2+, nylon wool adherent or phagocytic populations were removed from normal spleen effectors, the difference in spontaneous cell-mediated cytotoxicity between the H-2-deficient and the H-2-positive cells persisted. This result was also obtained when spleen cell effectors from nude mice or asialo GM1+ effectors, positively enriched by fluorescence-activated cell sorter, were used. The results show that the selectivity in the rejection of H-2-deficient cells was not determined in the afferent arm alone. The present data fit with a previously proposed model where natural killer cells would bind equally well to both major histocompatibility complex class I negative and class I positive target cells, but only the latter would be able to present a postbinding inhibitory signal allowing them to escape killing which results in outgrowth in vivo and poor cold target competition in vitro.
Similar articles
-
H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains.J Immunol. 1994 Dec 15;153(12):5482-90. J Immunol. 1994. PMID: 7989750
-
[Experimental analysis of intracerebral natural resistance against H-2+ and H-2- lymphomas grafted into the brain].No Shinkei Geka. 1989 Aug;17(8):717-23. No Shinkei Geka. 1989. PMID: 2586713 Japanese.
-
H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.J Immunol. 1988 Dec 15;141(12):4403-9. J Immunol. 1988. PMID: 3264312
-
Natural cytotoxicity against mouse hepatitis virus-infected target cells. I. Correlation of cytotoxicity with virus binding to leukocytes.J Immunol. 1986 Feb 15;136(4):1446-53. J Immunol. 1986. PMID: 3003198
-
Genetic control of natural cytotoxicity and hybrid resistance.Adv Cancer Res. 1980;31:227-85. doi: 10.1016/s0065-230x(08)60659-4. Adv Cancer Res. 1980. PMID: 6157312 Review. No abstract available.
Cited by
-
Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene.J Exp Med. 1993 Jan 1;177(1):201-5. doi: 10.1084/jem.177.1.201. J Exp Med. 1993. PMID: 8418201 Free PMC article.
-
Inhibitory receptors alter natural killer cell interactions with target cells yet allow simultaneous killing of susceptible targets.J Exp Med. 1999 Oct 4;190(7):1005-12. doi: 10.1084/jem.190.7.1005. J Exp Med. 1999. PMID: 10510090 Free PMC article.
-
Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors.J Exp Med. 2001 Nov 19;194(10):1519-30. doi: 10.1084/jem.194.10.1519. J Exp Med. 2001. PMID: 11714758 Free PMC article.
-
Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.Immunogenetics. 2017 Aug;69(8-9):547-556. doi: 10.1007/s00251-017-1011-9. Epub 2017 Jul 11. Immunogenetics. 2017. PMID: 28699110 Free PMC article. Review.
-
Altered natural killer cell repertoire in Tap-1 mutant mice.Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6520-4. doi: 10.1073/pnas.91.14.6520. Proc Natl Acad Sci U S A. 1994. PMID: 8022815 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials
Miscellaneous